Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis (Q46853343)
Jump to navigation
Jump to search
scientific article published on 30 December 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis |
scientific article published on 30 December 2013 |
Statements
1 reference
Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis (English)
1 reference
Mohssen Elalfy
1 reference
Yasser A Wali
1 reference
Mohamad Qari
1 reference
Ghazi Al Damanhouri
1 reference
Youssef Al-Tonbary
1 reference
Dilek Yazman
1 reference
Zakaria Al Hawsawi
1 reference
Zeynep Karakas
1 reference
Yurdanur Kilinc
1 reference
M Akif Yesilipek
1 reference
Mohamed Badr
1 reference
Usama Elsafy
1 reference
Mostafa Salama
1 reference
Yousryeia Abdel Rahman
1 reference
Shebl Shebl
1 reference
Anne Stilman
1 reference
Noemi Toiber Temin
1 reference
Fernando Tricta
1 reference
30 December 2013
1 reference
1 reference
61
1 reference
5
1 reference
879-884
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference